Skip to main content

Table 2 Summary of metabolic, HIV disease, and liver disease characteristics in HIV/HCV-coinfected patients at baseline and the end of follow-up

From: HCV eradication with IFN-based therapy does not completely restore gene expression in PBMCs from HIV/HCV-coinfected patients

Variable–median (IQR) Baseline Final p-value
Metabolic profile
 Glucose (mg/dL) 97.5 (83.8; 103) 93 (86.5; 96.5) 0.967
 Triglycerides (mg/dL) 108 (78.5; 169.5) 145 (99.5; 189.3) 0.063
 Cholesterol (mg/dL) 169 (139.5; 194.5) 183.5 (169.8; 208.5) 0.022
 LDL (mg/dL) 104 (76.3; 118.8) 110 (97; 135) 0.071
 HDL (mg/dL) 48 (36; 56.5) 36 (33; 50) 0.119
HIV disease profile
 CD4+ T-cells/mm3 678 (446; 911) 827 (588; 1131) 0.026
 CD8+ T-cells/mm3 946 (555; 1356) 1093 (840; 1308) 0.531
 HIV-viral load > 50 copies/mL (%) 0/28 (0%) 4/26 (15.4%) 0.982
Liver disease profile
 LSM (kPa) 11.9 (9.6; 19.9) 7.6 (5.9; 13.9.) 0.002
 FIB4 2.6 (1.9; 3.2) 1.7 (1.2; 2.1) 0.000
 AST (UI/L) 61 (42.5; 79.3) 19 (13.8; 25) 0.000
 ALT (UI/L) 71.5 (56; 100.5) 33.5 (26.5; 42) 0.000
 GGT (UI/L) 41 (35.5; 44) 33.5 (26.5; 42) 0.951
 Alkaline phosphatase (UI/L) 94.5 (78; 117) 95 (85; 120) 0.381
 INR 1 (1; 1.1) 1 (0.95; 1.1) 0.353
 Bilirubin (mg/dL) 0.6 (0.5; 1.15) 0.6 (0.4; 0.8) 0.177
 Albumin (g/dL) 4.3 (3.9; 4.6) 4.5 (4.2; 4.7) 0.045
  1. Statistics: The values are expressed as the median (IQR, interquartile range). P-values were calculated by generalized linear mixed models (GLMM) for paired samples
  2. HCV, hepatitis C virus; HIV, human immunodeficiency virus; LSM, liver stiffness measure; LDL, low-density lipoprotein; HDL, high-density lipoprotein; LSM; liver stiffness measure; FIB4; fibrosis-4 index; ALT, alanine aminotransferase; AST, aspartate transaminase; GGT, gamma-glutamyl transferase; INR, international normalized ratio